<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04951063</url>
  </required_header>
  <id_info>
    <org_study_id>GASTO-1080</org_study_id>
    <nct_id>NCT04951063</nct_id>
  </id_info>
  <brief_title>Fraction Dose Escalation of Split-course Adaptive Hypo-fractionated Concurrent Chemoradiotherapy in Locally Advanced Non-small Cell Lung Cancer</brief_title>
  <official_title>Increasing Single Radiation Dose in Radical Concurrent Radiochemotherapy for Locally Advanced Non-small Cell Lung Cancer: A Phase I Climbing Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective phase I study intends to explore the maximum tolerable single radiation dose&#xD;
      for locally advanced non-small cell lung cancer patients undergoing radical concurrent&#xD;
      radiochemotherapy at the same bioequivalent radiation dose&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective phase I study intends to explore the maximum tolerable single radiation dose&#xD;
      for locally advanced non-small cell lung cancer patients undergoing radical concurrent&#xD;
      radiochemotherapy at the same bioequivalent radiation dose.&#xD;
&#xD;
      All patients will receive segmented adaptive intensity-modulated radiotherapy once a day, 5&#xD;
      days a week. Three weeks after the end of the first course of radiotherapy, the efficacy of&#xD;
      therapy will be evaluated. Lung function and lung perfusion imaging will be also evaluated.&#xD;
      For patients whose tumors reached partial response and lung function can tolerate&#xD;
      radiotherapy supplements, the second course of radiotherapy were performed.&#xD;
&#xD;
      Under the premise of keeping the bioequivalent dose unchanged (BED=90GY), we will perform a&#xD;
      single radiotherapy dose climbing study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2021</start_date>
  <completion_date type="Anticipated">August 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment-induced ≥ Grade 3 toxicity (CTCAE 5.0 version)</measure>
    <time_frame>1 year</time_frame>
    <description>Grade 3 hematological toxicity, any level allergic reactions of drugs, and grade 3 radiation esophagitis are not considered dose-limiting toxicity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>2 months after radiotherapy</time_frame>
    <description>Proportion of patients with PR and CR at 2 months after radiotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>2-year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Locally Advanced Lung Carcinoma</condition>
  <arm_group>
    <arm_group_label>Concurrent radiotherapy and chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will receive segmented adaptive intensity-modulated radiotherapy once a day, 5 days a week. Three weeks after the end of the first course of radiotherapy, the therapy efficacy will be evaluated. Lung function and lung perfusion imaging will be also evaluated. For patients whose tumors reached partial response and lung function can tolerate radiotherapy supplements, The second course of radiotherapy will be performed.&#xD;
Under the premise of keeping the bioequivalent dose unchanged (BED=90GY), a single radiation dose climbing is carried out:&#xD;
Level 1: The first course: total dose (DT) 5100cGy/17f/300cGy, the second course: DT 1800cGy/6f/300cGy.&#xD;
Level 2: Thefirst course: DT 4000cGy/10f/400cGy, the second course DT 2400cGy/6f/400cGy.&#xD;
Level 3: The first course: DT 3000cGy/6f/500cGy, the second course DT 3000cGy/6f/500cGy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Concurrent chemotherapy and single radiation dose climbing</intervention_name>
    <description>Dose climbing process:&#xD;
The maximum single radiotherapy dose is defined as the maximum dose level at which ≤2 patients have ≥grade 3 toxicity, and ≤1 patient has ≥grade 4 toxicity. If a patient has multiple toxicities, only the highest level toxic event will be recorded.&#xD;
When one of the following two conditions are met, it can climb to the next gradient:&#xD;
The dose gradient has treated 6 patients, and at least 3 patients have been followed up for more than 3 months after radiotherapy, and no ≥ grade 3 toxicity occurred.&#xD;
The dose gradient has treated 6 patients and followed up for more than 3 months after radiotherapy. ≤2 patients had ≥grade 3 toxicity, and ≤1 patient had ≥grade 4 toxicity.&#xD;
If 1) and 2) are not satisfied, the enrollment will be terminated.&#xD;
Chemotherapy: docetaxel 25 mg/m2 was infused intravenously on D1 of weekly radiotherapy, the infusion time was 1 hour, and cisplatin 25 mg/m2.</description>
    <arm_group_label>Concurrent radiotherapy and chemotherapy</arm_group_label>
    <other_name>Radiotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Non-small cell lung cancer confirmed by histology.&#xD;
&#xD;
          -  Tumor size is measured according to RECIST standard.&#xD;
&#xD;
          -  Unresectable stage IIIA (N2) and IIIB/IIIC, confirmed by PET-CT/or chest and abdomen&#xD;
             CT, brain MRI, and whole body bone scan.&#xD;
&#xD;
          -  18-75 years old, regardless of gender.&#xD;
&#xD;
          -  The ECOG score is 0-1.&#xD;
&#xD;
          -  Newly treated or underwent neoadjuvant chemotherapy and/or immunotherapy.&#xD;
&#xD;
          -  Have not received chest radiotherapy in the past.&#xD;
&#xD;
          -  Serum hemoglobin ≥10 mg/dL, platelets ≥100000/μL, absolute neutrophil count ≥1500/μL.&#xD;
&#xD;
          -  Serum creatinine ≤1.25 times UNL or creatinine clearance ≥60 ml/min.&#xD;
&#xD;
          -  Serum bilirubin ≤1.5 times UNL, AST (SGOT) and ALT (SGPT) ≤2.5 times UNL, alkaline&#xD;
             phosphatase≤ 5 times UNL.&#xD;
&#xD;
          -  FEV1&gt;1 L.&#xD;
&#xD;
          -  CB6 normal range.&#xD;
&#xD;
          -  The patient and his family members agree and sign an informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other malignant tumors in the past or during treatment, except for non-melanoma of the&#xD;
             skin or carcinoma in situ of the cervix.&#xD;
&#xD;
          -  Any other diseases or conditions are contraindications to chemotherapy (such as active&#xD;
             infection, within 6 months after myocardial infarction, symptomatic heart disease,&#xD;
             including unstable angina, congestive heart failure or uncontrolled arrhythmia,&#xD;
             immunosuppressive therapy).&#xD;
&#xD;
          -  Pregnant or breastfeeding women, women who have not undergone a pregnancy test (within&#xD;
             14 days before the first dose), and pregnant women.&#xD;
&#xD;
          -  Those who are pregnant, breastfeeding or have fertility but have not taken&#xD;
             contraceptive measures.&#xD;
&#xD;
          -  People with bleeding tendency.&#xD;
&#xD;
          -  Those who participated in other clinical trials within 30 days before participating in&#xD;
             this experiment.&#xD;
&#xD;
          -  Drug addiction, long-term alcoholism, and AIDS patients.&#xD;
&#xD;
          -  People with uncontrollable seizures or loss of self-control due to mental illness.&#xD;
&#xD;
          -  People with a history of severe allergies or specific physique.&#xD;
&#xD;
          -  The researcher believes that the patient is inappropriate to participate in this&#xD;
             trial.&#xD;
&#xD;
        Exit criteria&#xD;
&#xD;
          -  The treatment cannot be carried out in accordance with the requirements of the&#xD;
             research protocol;&#xD;
&#xD;
          -  The patient has an allergic reaction ≥ grade 4 or a serious adverse reaction to the&#xD;
             study drug;&#xD;
&#xD;
          -  The patient is pregnant or has not used adequate contraceptive measures;&#xD;
&#xD;
          -  The researcher judges that the patient should not continue to participate the clinical&#xD;
             trial;&#xD;
&#xD;
          -  The subject asked to withdraw.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hui Liu, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun yat-sen universtiy cancer center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bo Qiu, Professor</last_name>
    <phone>+86-020-87343031</phone>
    <email>qiubo@sysucc.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sun yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bo Qiu, Professor</last_name>
      <phone>020-87343031</phone>
      <email>qiubo@sysucc.org.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpeño J, Wadsworth C, Melillo G, Jiang H, Huang Y, Dennis PA, Özgüroğlu M; PACIFIC Investigators. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017 Nov 16;377(20):1919-1929. doi: 10.1056/NEJMoa1709937. Epub 2017 Sep 8.</citation>
    <PMID>28885881</PMID>
  </reference>
  <reference>
    <citation>Gray JE, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Kurata T, Chiappori A, Lee KH, Cho BC, Planchard D, Paz-Ares L, Faivre-Finn C, Vansteenkiste JF, Spigel DR, Wadsworth C, Taboada M, Dennis PA, Özgüroğlu M, Antonia SJ. Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC-Update from PACIFIC. J Thorac Oncol. 2020 Feb;15(2):288-293. doi: 10.1016/j.jtho.2019.10.002. Epub 2019 Oct 14.</citation>
    <PMID>31622733</PMID>
  </reference>
  <reference>
    <citation>Cannon DM, Mehta MP, Adkison JB, Khuntia D, Traynor AM, Tomé WA, Chappell RJ, Tolakanahalli R, Mohindra P, Bentzen SM, Cannon GM. Dose-limiting toxicity after hypofractionated dose-escalated radiotherapy in non-small-cell lung cancer. J Clin Oncol. 2013 Dec 1;31(34):4343-8. doi: 10.1200/JCO.2013.51.5353. Epub 2013 Oct 21.</citation>
    <PMID>24145340</PMID>
  </reference>
  <reference>
    <citation>Uitterhoeve AL, Belderbos JS, Koolen MG, van der Vaart PJ, Rodrigus PT, Benraadt J, Koning CC, González González D, Bartelink H. Toxicity of high-dose radiotherapy combined with daily cisplatin in non-small cell lung cancer: results of the EORTC 08912 phase I/II study. European Organization for Research and Treatment of Cancer. Eur J Cancer. 2000 Mar;36(5):592-600.</citation>
    <PMID>10738123</PMID>
  </reference>
  <reference>
    <citation>Graham MV, Pajak TE, Herskovic AM, Emami B, Perez CA. Phase I/II study of treatment of locally advanced (T3/T4) non-oat cell lung cancer with concomitant boost radiotherapy by the Radiation Therapy Oncology Group (RTOG 83-12): long-term results. Int J Radiat Oncol Biol Phys. 1995 Feb 15;31(4):819-25.</citation>
    <PMID>7860394</PMID>
  </reference>
  <reference>
    <citation>Qiu B, Li QW, Ai XL, Wang B, Huan J, Zhu ZF, Yu GH, Ji M, Jiang HH, Li C, Zhang J, Chen L, Guo JY, Zhou Y, Liu H. Investigating the loco-regional control of simultaneous integrated boost intensity-modulated radiotherapy with different radiation fraction sizes for locally advanced non-small-cell lung cancer: clinical outcomes and the application of an extended LQ/TCP model. Radiat Oncol. 2020 May 27;15(1):124. doi: 10.1186/s13014-020-01555-x.</citation>
    <PMID>32460796</PMID>
  </reference>
  <reference>
    <citation>Glinski K, Socha J, Wasilewska-Tesluk E, Komosinska K, Kepka L. Accelerated hypofractionated radiotherapy with concurrent full dose chemotherapy for locally advanced non-small cell lung cancer: A phase I/II study. Radiother Oncol. 2020 Jul;148:174-180. doi: 10.1016/j.radonc.2020.04.033. Epub 2020 Apr 24.</citation>
    <PMID>32388152</PMID>
  </reference>
  <reference>
    <citation>Kong C, Zhu X, Shi M, Wang L, Chen C, Tao H, Jiang N, Yan P, Zhao L, Song X, He X. Survival and Toxicity of Hypofractionated Intensity Modulated Radiation Therapy in 4 Gy Fractions for Unresectable Stage III Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2020 Jul 15;107(4):710-719. doi: 10.1016/j.ijrobp.2020.03.038. Epub 2020 Apr 7.</citation>
    <PMID>32275994</PMID>
  </reference>
  <reference>
    <citation>Hanna N, Neubauer M, Yiannoutsos C, McGarry R, Arseneau J, Ansari R, Reynolds C, Govindan R, Melnyk A, Fisher W, Richards D, Bruetman D, Anderson T, Chowhan N, Nattam S, Mantravadi P, Johnson C, Breen T, White A, Einhorn L; Hoosier Oncology Group; US Oncology. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. J Clin Oncol. 2008 Dec 10;26(35):5755-60. doi: 10.1200/JCO.2008.17.7840. Epub 2008 Nov 10.</citation>
    <PMID>19001323</PMID>
  </reference>
  <reference>
    <citation>Spoelstra FO, Pantarotto JR, van Sörnsen de Koste JR, Slotman BJ, Senan S. Role of adaptive radiotherapy during concomitant chemoradiotherapy for lung cancer: analysis of data from a prospective clinical trial. Int J Radiat Oncol Biol Phys. 2009 Nov 15;75(4):1092-7. doi: 10.1016/j.ijrobp.2008.12.027. Epub 2009 Mar 26.</citation>
    <PMID>19327915</PMID>
  </reference>
  <reference>
    <citation>Gielda BT, Marsh JC, Zusag TW, Faber LP, Liptay M, Basu S, Warren WH, Fidler MJ, Batus M, Abrams RA, Bonomi P. Split-course chemoradiotherapy for locally advanced non-small cell lung cancer: a single-institution experience of 144 patients. J Thorac Oncol. 2011 Jun;6(6):1079-86. doi: 10.1097/JTO.0b013e3182199a7c.</citation>
    <PMID>21532501</PMID>
  </reference>
  <reference>
    <citation>Furuse K, Fukuoka M, Kawahara M, Nishikawa H, Takada Y, Kudoh S, Katagami N, Ariyoshi Y. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol. 1999 Sep;17(9):2692-9.</citation>
    <PMID>10561343</PMID>
  </reference>
  <reference>
    <citation>Belani CP, Choy H, Bonomi P, Scott C, Travis P, Haluschak J, Curran WJ Jr. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol. 2005 Sep 1;23(25):5883-91. Epub 2005 Aug 8. Erratum in: J Clin Oncol. 2006 Apr 20;24(12):1966.</citation>
    <PMID>16087941</PMID>
  </reference>
  <reference>
    <citation>Albain KS, Swann RS, Rusch VW, Turrisi AT 3rd, Shepherd FA, Smith C, Chen Y, Livingston RB, Feins RH, Gandara DR, Fry WA, Darling G, Johnson DH, Green MR, Miller RC, Ley J, Sause WT, Cox JD. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet. 2009 Aug 1;374(9687):379-86. doi: 10.1016/S0140-6736(09)60737-6. Epub 2009 Jul 24.</citation>
    <PMID>19632716</PMID>
  </reference>
  <reference>
    <citation>Vokes EE, Herndon JE 2nd, Kelley MJ, Cicchetti MG, Ramnath N, Neill H, Atkins JN, Watson DM, Akerley W, Green MR; Cancer and Leukemia Group B. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol. 2007 May 1;25(13):1698-704. Epub 2007 Apr 2.</citation>
    <PMID>17404369</PMID>
  </reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 26, 2021</study_first_submitted>
  <study_first_submitted_qc>June 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 6, 2021</study_first_posted>
  <last_update_submitted>July 11, 2021</last_update_submitted>
  <last_update_submitted_qc>July 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Hui Liu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Locally advanced non-small cell lung cancer</keyword>
  <keyword>Radical concurrent radiochemotherapy</keyword>
  <keyword>Single radiation dose climbing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

